Background: Intrahepatic cholangiocarcinoma (IHCCA) is an aggressive tumor for which surgical resection is a mainstay of treatment. However, recurrence after resection is common associated with a poor prognosis. Studies regarding recurrence of mass-forming IHCCA are rare; therefore, we investigated the pattern with our dataset. Methods: We retrospectively reviewed the medical and pathological records of 50 mass-forming IHCCA patients who underwent hepatic resection between January 2004 and December 2009 in order to determine the patterns of recurrence and prognosis. All demographic and operative parameters were analyzed for their effects on recurrence-free survival.
Introduction
Intrahepatic cholangiocarcinoma is the second most common primary malignancy of the liver (Khan SA et al., 2002) . Most patients have advanced disease at the time of presentation and die within 1 year, only subset of patients are candidates for curative treatment (Tan JCC et al., 2008; Luvira V et al., 2002) . The mainstay of treatment of intrahepatic cholangiocarcinoma is surgical resection (Bridgewater J et al., 2014; Konstantinidis IT et al., 2016) ; however, most patients experience recurrence despite completely removing the tumor (Konstantinidis IT et al., 2016; Spolverato G et al., 2016) and the subsequent prognosis is very poor (Spolverato G et al., 2016) . The data on the pattern of recurrence of cholangiocarcinoma would be useful for determining the best operative procedure and further treatment strategies.
Several studies have been conducted to investigate the pattern of recurrence of all types of intrahepatic cholangiocarcinoma (Jung SJ et al., 2012; Weber SM et al., 2001; Yamamoto M and Ariizumi S, 2006; Hyder O et al., 2013) . Recurrence after hepatic resection for intrahepatic cholangiocarcinoma is common (Hyder O et De jong MC et al., 2011) , and the recurrence rate is significantly higher in patients with the mass-forming type. Recurrences occur equally at the intrahepatic and extrahepatic sites. The authors suggest adjuvant treatment is likely to have an impact on patient outcomes (Hyder O et al., 2013) . According to their gross features, intrahepatic cholangiocarcinoma includes the mass-forming, periductal-infiltrating, and intraductal-growth (IG) types (Yamamoto J et al., 1993) . Recent evidence shows that there are differences in nature among the three type of intrahepatic cholangiocarcinoma; particularly the mass-forming type, which is believed to originate from progenitor cells at the canals of Hering (Aishima S and Oda Y, 2015; Nakanuma Y et al., 2010) . The mass-forming cholangiocarcinoma might have a specific pattern of recurrence.
To achieve a better understanding of the pattern of recurrence of mass-forming intrahepatic cholangiocarcinoma (MF-IHCCA), we investigated the rate and location of recurrences of mass-forming intrahepatic cholangiocarcinoma. We additionally analyzed the association between recurrence-free and peri-operative parameters.
Materials and methods
This retrospective study ran between January 2004 and December 2009. We reviewed the medical records of all the patients who underwent curative-intent hepatic resection for hepatobiliary neoplasm at Srinagarind Hospital, Khon Kaen University. The definition of massforming intrahepatic cholangiocarcinoma in this study included pathologically-confirmed adenocarcinoma of the biliary tree and the presence of a visible mass lesion without any signs of periductal infiltration or intraductal neoplasm. After reviewing the records, 50 cases of mass-forming intrahepatic cholangiocarcinoma were found.
Regarding the treatment protocol at our center, all of the patients were evaluated for resectability using crossectional imaging (i.e., computed tomography, or magnetic resonance imaging). The intent of all of the operations was to at least remove all visible tumors. All surgical specimens were sent to the Department of Pathology for pathological diagnosis and staging. All patients were followed-up for tumor recurrence and death.
Ethical consideration
The Institutional Review Board (IRB), Office of Human Research Ethics, Khon Kaen University, reviewed and approved the present study (HE571293).
Outcome variables
The primary outcome of this study was the recurrence rate and sites of recurrence of tumors. We also investigated recurrence-free survival and the factors effecting it, including tumor number, stage of the tumor, tumor grade, types of operation, and surgical margin status.
Statistical analysis
The data are presented as medians (min: max), or as counts and percentages. A survival analysis was performed using the Kaplan-Meier analysis; patients who died before recurrence of a tumor was detected were censored. Comparisons among groups were analyzed using a log-rank test. All statistical analyses were performed using STATA version 10.
Results

Clinical and pathological characteristics
Between January 2004 and December 2009, fifty patients underwent curative-intent hepatectomy for mass-forming intrahepatic cholangiocarcinoma. The median age at diagnosis was 57.2 years (range, 32-72). The male to female ratio was 1 (male=26, female=24).
Upper abdominal pain (82%) was the most common presentation. According to number of tumors, the majority of patients (86%) had a single tumor; the mean tumor size was 6.49 cm (95%CI: 5.17-7.80).
According to AJCC staging, most of the patients had advanced disease, stage 4, according to lymph node involvement, at the time of surgery. Most of the tumors were well-differentiated.
Regarding the surgery, right-sided hepatectomy outnumbered left-sided hepatectomy 3 to 1 (78% vs. 22%). The margin-free surgical status was achieved in about half of the patients. Lymph node dissection was performed in 26 (52%) patients.
Patients' survival
The respective 1-, 2-and 3-year survival rate was 32% (95%CI: 19.7-45), 16% (95%CI: 7.5-27.4), and 6% (95%CI: 0.2-12.0). The median survival time was 188 days (95%CI: 1.60-14.9) (Figure 1a ).
Recurrence-free survival and recurrence pattern
During the study period, recurrence was detected in 40 patients. The rate of recurrence was 80% (40/50). The remaining patients died without evidence of recurrence. The respective 1-, 2-, and 3-year recurrence-free survival rate was 16.2% (95%CI: 6.6-29.4), 5.4% (95%CI: 1.0-15.8), and 2.7% (95%CI: 0.2-12.0). The median recurrence-free survival time was 188 days (95%CI: 149-299) (Figure 1b) .
Table1 lists the clinicopathological characteristics and univariate analyses for recurrence-free survival. Several factors seemed to be related with recurrence-free survival but the differences were not statistically significant (viz., AJCC staging, surgical margin status (Figure2) and postoperative chemotherapy (Figure3)).
About half of the patients experienced a solitary recurrence (n =22; 55.0%). The most frequent site of recurrence was the surgical margin (n=18; 45.0%), followed by regional lymph nodes (n =17; 42.5%), and Table 2 .
According to the side of the hepatectomy, the patients who underwent left-sided hepatectomy had more loco-regional recurrences (i.e., surgical margin, liver remnant, and regional lymph node). The distant organ recurrences were observed only in the patients who underwent right-sided hepatectomy (Figure 4) .
Among the 18 patients who experienced surgical margin recurrences, 14 (77.8%) had microscopic tumors on the surgical margin after the first operation. Of the 27 patients (29.6%) with microscopic tumors on the surgical 
Discussion
Our study shows that mass-forming cholangiocarcinoma has a demonstrably poor prognosis. The overall and disease-free survival in our study was poor compared with other series (De jong MC et al., 2011; Suzuki S et al., 2002; Endo I et al., 2008) , but comparable to a previous study at our center (Bhudhisawasdi V et al., 2012) . We aimed to determine the pattern of initial recurrence of mass-forming intrahepatic cholangiocarcinoma. We found that after hepatectomy, the pattern of recurrence of cholangiocarcinoma was disrupted, which is to say unpredictable. Although intrahepatic recurrences were observed in most of cases with multiple sites of recurrences, but solitary extrahepatic recurrences were also observe. Several researchers have concluded that lymph node involvement of intrahepatic cholangiocarcinoma represents systemic disease (Morine Y et al., 2012; Morine Y and Shimada M, 2015) . The current study had very high (64%) prevalence of lymph node involvement compare with previous reports (Konstantinidis IT et al., 2016; Ribero D et al., 2012) , which may explain why our study had a higher rate of systemic recurrence than previous reports. The present study confirmed that regional lymphadenectomy may not improve survival, as reported by others (Morine Y and Shimada M, 2015; Wu ZF et al., 2015; Kim DH et al., 2015) . We found no relationship between lymph node dissection and the rate of regional lymph node recurrences.
As for making changes in treatment policy, extension of surgical procedures may decrease the recurrence of surgical margins and regional lymph node recurrences. The other sites of recurrence can only be treated using systemic therapy. Others demonstrated that intrahepatic metastasis (liver remnant recurrence) was the salient feature after surgery (Spolverato G et al., 2016; Suzuki S et al., 2002) , and this could not be prevented by extension of surgery; so, adjuvant chemotherapy may add some benefit regarding recurrence of tumors (Suzuki S et al., 2002) . Our study failed to demonstrate any relationship between routine lymph node dissection and regional lymph node recurrence, but we found that patients who had received post-operative chemotherapy trended to have better recurrence-free survival, albeit not statistically significant-perhaps owing to the small sample size. Our findings were, however, consistent with previous studies that found that mass-forming cholangiocarcinoma represents an advance of the disease, such that there is a higher chance of systemic recurrence, so adjuvant chemotherapy would be needed (Konstantinidis IT et al., 2016; Hyder O et al., 2013; Suzuki S et al., 2002; Wirasorn K et al., 2013) .
Although our study focused on mass-forming cholangiocarcinoma and had quite a high number compared with previous reports (Weber SM et al., 2001; Suzuki S et al., 2002) , this study had limitations. First, the retrospective nature may introduce a bias vis-à-vis the pattern of recurrence. Second, during the current study, there was no uniformity of treatment for intrahepatic cholangiocarcinoma; whether it was width of surgical margin, routine lymph node dissection, or postoperative chemotherapy. Finally, although we attempted to identify only mass-forming cholangiocarcinoma by excluding cases with evidence of periductal infiltration Regional lymph node and aortocaval lymph node 1(2.4%)
Regional lymph node and bone 1(2.4%)
Regional lymph node and peritoneum 1(2.4%) 
